Novo Nordisk's Buyback and CagriSema Data Address Different Questions Than Its US Problem
Novo Nordisk is returning capital to shareholders at a steady clip while its most closely watched pipeline asset posts encouraging numbers in a subgroup of patients. Neither…
TR
By Tom Reyes · Markets Editor
Oct 22 05:31 ETSource: AD HOC NEWS
From the source
Read at ad-hoc-news.deNovo Nordisk's Buyback and CagriSema Data Address Different Questions Than Its US Problem
Novo Nordisk is returning capital to shareholders at a steady clip while its most closely watched pipeline asset posts encouraging numbers in a subgroup of patients. Neither development, on its own, answers the question hanging over the stock: how much pressure is building in the US business before new medicines can shift the narrative?
